Tarextumab
Appearance
Monoclonal antibody | |
---|---|
Type | ? |
Source | Human |
Target | Notch 2, Notch 3 |
Clinical data | |
Other names | OMP-59R5 |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C6338H9804N1700O1990S48 |
Molar mass | 143196.94 g·mol−1 |
Tarextumab (formerly OMP-59R5) is a fully human monoclonal antibody targeting the Notch 2/3 receptors. It is being tested as a possible treatment for cancer. In January 2015, the US FDA granted orphan drug designation to tarextumab for the treatment of pancreatic cancer and lung cancer.[1] Two early stage clinical trials have reported encouraging results.[1]
See also
[edit]- Notch signaling pathway, e.g. in embryo tissue development
References
[edit]